AU2009249186B2 - Imidazo [1, 2-a] pyridine compounds as GABA-A receptor modulators - Google Patents

Imidazo [1, 2-a] pyridine compounds as GABA-A receptor modulators Download PDF

Info

Publication number
AU2009249186B2
AU2009249186B2 AU2009249186A AU2009249186A AU2009249186B2 AU 2009249186 B2 AU2009249186 B2 AU 2009249186B2 AU 2009249186 A AU2009249186 A AU 2009249186A AU 2009249186 A AU2009249186 A AU 2009249186A AU 2009249186 B2 AU2009249186 B2 AU 2009249186B2
Authority
AU
Australia
Prior art keywords
methyl
substituted
imidazo
compound
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009249186A
Other languages
English (en)
Other versions
AU2009249186A1 (en
Inventor
Una Campbell
Milan Chytil
Qun Kevin Fang
Paul T. Grover
Seth C. Hopkins
Kerry L. Spear
Frank Xinhe Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of AU2009249186A1 publication Critical patent/AU2009249186A1/en
Assigned to SUNOVION PHARMACEUTICALS INC. reassignment SUNOVION PHARMACEUTICALS INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: SEPRACOR INC.
Application granted granted Critical
Publication of AU2009249186B2 publication Critical patent/AU2009249186B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2009249186A 2008-05-19 2009-05-19 Imidazo [1, 2-a] pyridine compounds as GABA-A receptor modulators Ceased AU2009249186B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5443208P 2008-05-19 2008-05-19
US5443708P 2008-05-19 2008-05-19
US61/054,432 2008-05-19
US61/054,437 2008-05-19
PCT/US2009/044525 WO2009143156A2 (en) 2008-05-19 2009-05-19 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS

Publications (2)

Publication Number Publication Date
AU2009249186A1 AU2009249186A1 (en) 2009-11-26
AU2009249186B2 true AU2009249186B2 (en) 2014-05-22

Family

ID=41031732

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009249186A Ceased AU2009249186B2 (en) 2008-05-19 2009-05-19 Imidazo [1, 2-a] pyridine compounds as GABA-A receptor modulators

Country Status (6)

Country Link
US (2) US8497278B2 (enExample)
EP (1) EP2300470A2 (enExample)
JP (2) JP5774982B2 (enExample)
AU (1) AU2009249186B2 (enExample)
CA (1) CA2724842A1 (enExample)
WO (1) WO2009143156A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008314870A1 (en) * 2007-10-24 2009-04-30 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
JP5641664B2 (ja) 2009-10-30 2014-12-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ イミダゾ［１，２−ｂ］ピリダジン誘導体およびＰＤＥ１０阻害剤としてのそれらの使用
RU2608611C2 (ru) 2009-11-05 2017-01-23 Юниверсити Оф Нотр Дам Дю Лак СОЕДИНЕНИЯ ИМИДАЗО[1,2-а] ПИРИДИНА, ИХ СИНТЕЗ И СПОСОБЫ ПРИМЕНЕНИЯ
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
JP5911476B2 (ja) 2010-05-26 2016-04-27 スノビオン プハルマセウトイカルス インコーポレイテッド ヘテロアリール化合物及びその使用方法
EP2691392A1 (en) * 2011-03-31 2014-02-05 EMBLEM Technology Transfer GmbH Imidazo [1,2-a]pyridine compounds for use in therapy
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
RU2014150494A (ru) * 2012-05-30 2016-07-20 Ф. Хоффманн-Ля Рош Аг Пирролидиногетероциклы
AU2013283426B2 (en) 2012-06-26 2018-02-22 Janssen Pharmaceutica Nv Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological or metabolic disorders
WO2014009305A1 (en) 2012-07-09 2014-01-16 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
WO2014187922A1 (en) 2013-05-24 2014-11-27 Iomet Pharma Ltd. Slc2a transporter inhibitors
WO2017049321A1 (en) 2015-09-17 2017-03-23 Miller Marvin J Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection
EP3153506B1 (en) * 2015-10-07 2017-12-13 Sanko Tekstil Isletmeleri San. Ve Tic. A.S. Isoxazoles, a process for their preparation and uses thereof
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
AU2016358100B2 (en) 2015-11-19 2021-05-27 Incyte Corporation Heterocyclic compounds as immunomodulators
KR20180088462A (ko) 2015-12-10 2018-08-03 바이엘 파마 악티엔게젤샤프트 수면-관련 호흡기 장애의 치료를 위한 TASK-1 및 TASK-2 채널의 차단제로서의 2-페닐-3-(피페라지노메틸)이미다조[1,2-a]피리딘 유도체
WO2017097671A1 (de) 2015-12-10 2017-06-15 Bayer Pharma Aktiengesellschaft Substituierte perhydropyrrolo[3,4-c]pyrrol-derivate und ihre verwendung
TW201726623A (zh) 2015-12-17 2017-08-01 英塞特公司 作為免疫調節劑之雜環化合物
TWI850624B (zh) 2015-12-22 2024-08-01 美商英塞特公司 作為免疫調節劑之雜環化合物
TW201808950A (zh) 2016-05-06 2018-03-16 英塞特公司 作為免疫調節劑之雜環化合物
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
DK3472167T3 (da) 2016-06-20 2022-09-05 Incyte Corp Heterocykliske forbindelser som immunomodulatorer
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
JOP20190005A1 (ar) 2016-07-20 2019-01-20 Bayer Ag مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها
CN106279123B (zh) * 2016-08-15 2018-09-04 郑州大学 3-(苯磺酰甲基)咪唑并杂环类化合物及其合成方法
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
EA202192558A1 (ru) * 2016-12-14 2021-12-07 Байер Акциенгезельшафт Замещенные диазагетеробициклические соединения и их применение
ES2929193T3 (es) 2016-12-22 2022-11-25 Incyte Corp Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de la internalización de PD-L1
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
IL295660A (en) 2016-12-22 2022-10-01 Incyte Corp Benzooxazole derivatives as immunomodulators
CN107163039A (zh) * 2017-05-11 2017-09-15 浙江工业大学 一种6‑甲基‑2‑对甲苯基咪唑并[1,2‑a]吡啶‑3‑甲醛的制备方法
JOP20190284A1 (ar) 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
WO2018227427A1 (en) 2017-06-14 2018-12-20 Bayer Aktiengesellschaft Substituted bridged diazepane derivatives and use thereof
RS64055B1 (sr) 2018-03-30 2023-04-28 Incyte Corp Heterociklična jedinjenja kao imunomodulatori
EP4219492B1 (en) 2018-05-11 2024-11-27 Incyte Corporation Heterocyclic compounds as immunomodulators
IL279266B2 (en) * 2018-06-13 2024-03-01 Hoffmann La Roche New isoxazolyl ether derivatives as gaba a alpha5 pam
CN110964020B (zh) * 2018-09-28 2022-06-14 中国科学院大连化学物理研究所 一种制备3’,4’-二氢螺[吲哚啉-3,2’-吡咯]化合物的方法
AU2019416589B2 (en) * 2018-12-29 2023-04-06 Wuhan Ll Science And Technology Development Co., Ltd. Heterocyclic compound intermediate, preparation method therefor and application thereof
JP7665593B2 (ja) 2019-08-09 2025-04-21 インサイト・コーポレイション Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩
EP4037773A1 (en) 2019-09-30 2022-08-10 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
BR112022009031A2 (pt) 2019-11-11 2022-10-11 Incyte Corp Sais e formas cristalinas de um inibidor de pd-1/pd-l1
CN114380819B (zh) * 2020-10-22 2024-08-23 鲁南制药集团股份有限公司 一种唑吡坦中间体化合物
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
EP4240739A1 (en) 2020-11-06 2023-09-13 Incyte Corporation Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002557A2 (en) * 2000-06-30 2002-01-10 Neurogen Corporation 2-phenylimidazo[1,2-a]pyridine derivatives: a new class of gaba brain receptor ligands
EP1845098A1 (en) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB991589A (en) * 1963-04-30 1965-05-12 Selvi & C Lab Bioterapico Novel [1,2-ª‡]imidazopyridines and a process for the manufacture thereof
US3489755A (en) * 1966-08-03 1970-01-13 Pfizer & Co C Imidazo (1,2-b) pyridazines
US4242513A (en) * 1979-03-05 1980-12-30 Appleton Papers Inc. Lactone compounds containing a heterocyclic radical
GB8305245D0 (en) * 1983-02-25 1983-03-30 Fujisawa Pharmaceutical Co Imidazo-heterocyclic compounds
FR2568880B1 (fr) * 1984-08-07 1986-12-12 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
ES2032455T3 (es) 1986-01-22 1993-02-16 Synthelabo Procedimiento para preparar derivados de 3-acilaminometil-imidazo (-1,2-a)piridinas.
WO1989001333A1 (en) * 1987-08-07 1989-02-23 The Australian National University IMIDAZO[1,2-b]PYRIDAZINES
IN179789B (enExample) * 1992-02-10 1997-12-06 Council Scient Ind Res
FR2714907B1 (fr) * 1994-01-07 1996-03-29 Union Pharma Scient Appl Nouveaux dérivés de l'Adénosine, leurs procédés de préparation, compositions pharmaceutiques les contenant.
JPH09176165A (ja) * 1995-12-25 1997-07-08 Nippon Nohyaku Co Ltd イミダゾ［１，２−ａ］ピリジン誘導体、その製法およびその用途
US6514969B2 (en) * 2000-08-16 2003-02-04 Boehringer Ingelheim Pharma Kg β-amyloid inhibitors, processes for preparing them, and their use in pharmaceutical compositions
DE10040016A1 (de) * 2000-08-16 2002-02-28 Boehringer Ingelheim Pharma Neue beta-Amyloid Inhibitoren, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
SE0100567D0 (sv) * 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
WO2005044818A2 (en) 2003-10-28 2005-05-19 Sepracor, Inc. Imidazo[1,2-a]pyridine anxiolytics
WO2005080355A1 (en) * 2004-02-12 2005-09-01 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands
ES2321858T3 (es) * 2004-11-11 2009-06-12 Ferrer Internacional, S.A. Compuestos de imidazo(1,2-a)piridina, composiciones, usos y metodos relacionados.
MY147647A (en) * 2005-03-21 2012-12-31 S Bio Pte Ltd Imidazo [1,2-a] pyridine derivatives : preparation and pharmaceutical applications
US7666880B2 (en) * 2005-03-21 2010-02-23 S*Bio Pte Ltd. Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications
EP2308870A3 (en) * 2005-06-01 2011-10-19 UCB Pharma S.A. 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses
CA2618370A1 (en) * 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Oxazolopyridine derivatives as sirtuin modulators
EP1959959B1 (en) * 2005-12-06 2013-04-10 Merck Sharp & Dohme Corp. Morpholine carboxamide prokineticin receptor antagonists
RU2468014C2 (ru) * 2006-08-24 2012-11-27 Острэйлиен Ньюклиар Сайенс Энд Текнолоджи Организейшн Фторсодержащие лиганды для нацеливания периферических бензодиазепиновых рецепторов
WO2008058126A2 (en) * 2006-11-06 2008-05-15 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
EP1974729A1 (en) * 2007-03-28 2008-10-01 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002557A2 (en) * 2000-06-30 2002-01-10 Neurogen Corporation 2-phenylimidazo[1,2-a]pyridine derivatives: a new class of gaba brain receptor ligands
EP1845098A1 (en) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands

Also Published As

Publication number Publication date
JP2011523945A (ja) 2011-08-25
WO2009143156A3 (en) 2010-01-14
JP2015180633A (ja) 2015-10-15
JP6211556B2 (ja) 2017-10-11
AU2009249186A1 (en) 2009-11-26
WO2009143156A2 (en) 2009-11-26
US8497278B2 (en) 2013-07-30
CA2724842A1 (en) 2009-11-26
EP2300470A2 (en) 2011-03-30
US20110166146A1 (en) 2011-07-07
JP5774982B2 (ja) 2015-09-09
US20130289013A1 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
AU2009249186B2 (en) Imidazo [1, 2-a] pyridine compounds as GABA-A receptor modulators
AU2017348826B2 (en) Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor
JP5766820B2 (ja) Ｐｉ３キナーゼ阻害剤としての複素環化合物
EP3356345B1 (en) Heteroaryl derivatives as sepiapterin reductase inhibitors
CA2798634C (en) Pyridone and aza-pyridone compounds and methods of use
AU2011258436B2 (en) Soluble guanylate cyclase activators
CA3121408A1 (en) Heteroaromatic derivatives for use as regulator, preparation method therefor and use thereof
AU2018301696B8 (en) Heterocyclic inhibitors of ATR kinase
US20210393623A1 (en) Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
KR101824299B1 (ko) 피롤로[2, 1-f][1, 2, 4]트리아진계 화합물, 그 제조방법 및 용도
US12286406B2 (en) Inhibitors of receptor interacting protein kinase I for the treatment of disease
MX2012010050A (es) Inhibidores de pirrolopirazina cinasa.
AU2014324595A1 (en) Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
TW201247673A (en) Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders
US20040092533A1 (en) Imidazo-pyrimidine derivatives as ligands for gaba receptors
AU2007309149A1 (en) Bicyclic triazoles as protein kinase modulators
AU2011240808A1 (en) 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of JAK kinases
CA3225285A1 (en) Pi3k.alpha. inhibitors and methods of use thereof
EP4532485A1 (en) Tyk2 inhibitors and uses thereof
JP2017526685A (ja) 置換縮環ピリミジンおよびその使用
TW202517633A (zh) 作為選擇性細胞毒性劑之四氫喹唑啉衍生物
JP2025529923A (ja) Ｒａｆキナーゼの阻害のためのナフチリジン化合物
EA046365B1 (ru) Ингибиторы взаимодействующей с рецептором протеинкиназы i для лечения заболевания
AU2015201991A1 (en) 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of JAK kinases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired